Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Nasvax Advances Most in Three Months on Trial of Liver Treatment

Nasvax Ltd. rose the most in almost three months after its parent company Biomedix Incubator Ltd. said Nasvax’s Phase 2a clinical trial of a treatment for fatty liver was successful.

Nasvax shares climbed as much as 8.9 percent, the biggest intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3 percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv. Biomedix increased 3.6 percent to 0.607 shekel.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.